QrumPharma acquired by MannKind Corp.

One of our longstanding clients, QrumPharma LLC based in Doylestown, PA, USA, has been acquired by MannKind Corporation just recently.

See full details in the press release here: https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-expands-its-pipeline-acquisition-qrumpharma-inc

We are delighted that this project has come to such a huge success and thank the team at QrumPharma for the longstanding and very amicable cooperation. We wish all of you, but also of course the project for developing inhaled Clofazimine for the treatment of NTM, utmost success in the future!

Free rapid scientific advice for COVID-19 treatments or vaccines

EMA has put in place a rapid scientific advice procedure for potential COVID-19 treatments and vaccines, which is free of charge.

The rapid procedure reduces review time to a maximum of 20 days (from 40-70 days), with no pre-specified submission deadlines.

In addition, flexibility can be agreed on a case-by-case basis on the type and extent of the briefing dossier.

For more information, see:

EMA and the COVID-19 EMA pandemic Task Force can provide early guidance to developers whose development plan is not yet suitable for formal rapid scientific advice.

Contact us if you need assistance in preparing such a submission. We will make sure that the documents are diligently prepared so that you can get the most out of such a scientific advice procedure.

Covid-19 associated with vascular dysfunction

Covid-19 associated with vascular dysfunction, thrombosis, and dysregulated inflammation. This may have impact on future therapies.

Find more details here:


Click here to contact us!

Many approved drugs potentially beneficial for Covid-19

Nearly a dozen approved drugs could be effective against Covid-19, a study published in Nature says.

Find more details here:



Click here to contact us!

ACliRA Consulting can help your Covid-19 Development!

Do you consider initiating a clinical study in Covid-19?

We have huge experience in designing and conducting clinical studies in respiratory infectious diseases. Designing your clinical trial or whole development plan for investigating new treatments against COVID-19 (SARS-CoV-2) will be our top priority! Please contact us immediately if you need help and would like to leverage our experience for making new treatments against COVID-19 available for patients as soon as possible.

Click here to contact us!

Successful clinical development. Period.
Hohmannsweg 8, 35085 Ebsdorfergrund, Germany